Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL17646307 | 1.00 | PRSS1 (0.57) | PRSS1TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL22150080 | 1.00 | PRSS1 (0.57) | PRSS1TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL17646389 | 1.00 | PRSS1 (0.57) | PRSS1TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL28341588 | 1.00 | PRSS1 (0.57) | PRSS1TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL17646253 | 1.00 | PRSS1 (0.57) | PRSS1TPSAB1 | |
| SCHEMBL17661718 | 0.94 | — | — | |
| SCHEMBL17661717 | 0.94 | — | — | |
| SCHEMBL17665982 | 0.94 | — | — | |
| SCHEMBL17646303 | 0.94 | — | — | |
| SCHEMBL17646352 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332464-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210017167-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3204352-B1 | INHIBITORS OF LYSINE GINGIPAIN | CORTEXYME INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10676470-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190322659-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10301301-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180346460-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-12-06 | — | — | US | disclosed |
| US-9988375-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170349537-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9758473-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160096830-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346460-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-20190322659-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-20210017167-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-10676470-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-20170349537-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-20160096830-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-11332464-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
| US-10301301-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | PRSS1 55/4885TPSAB1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.